Overview

• Stevanato Q3 revenue grows 9% to €303.2 mln, beating analyst expectations

• Adjusted EPS for Q3 was €0.14, maintaining fiscal 2025 guidance

• Revenue growth driven by high-value solutions and favorable shipment timing

Outlook

• Stevanato maintains fiscal 2025 revenue guidance of €1.160 bln to €1.190 bln

• Stevanato expects 2025 adjusted EBITDA of €288.5 mln to €301.8 mln

• Stevanato projects 2025 adjusted diluted EPS of €0.50 to €0.54

Result Drivers

• BDS SEGMENT GROWTH - Revenue from the Biopharmaceutical and Diagnostic Solutions Segment grew 14%, driven by high-value solutions and favorable shipment timing

• HIGH-VALUE SOLUTIONS - Revenue from high-value solutions increased 47% to a record €147.9 million, driven by demand for Nexa syringes and EZ-fill vials

• SHIPMENT TIMING - Favorable timing of product shipments added approximately €10 million to BDS Segment revenue

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Stevanato Group SpA is $28.00, about 10.7% above its November 5 closing price of $25.00

• The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 36 three months ago

Press Release: ID:nBwg7NwCa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)